Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 341-360 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 341 | NeevCloud lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable because no direct positive evidence survived the 90-day recent evidence window in the retained reviewed sources. Why now: Why now is weak: despite membership rationale referring to partnerships and orbital data center / AI inferencing context, the retained reviewed sources contain zero evidence after recent evidence window and no citable article summaries. Caveats: Phase-2 membership rationale references, and: but no summaries or direct evidence are retained here for factual claims. The reviewed sources itself says NeevCloud is space-adjacent and not clearly a qualifying space company. |
| 342 | Neo Space Group lowweak | Opp 1 Risk 2 | Thesis: Potential opportunity exists if Neo Space Group is a meaningful customer or distribution node for satellite imagery supply to the Saudi government, but the reviewed sources does not provide available direct evidence within the recent evidence window to assess durability or monetization. Why now: No validated near-term or durable timing signal is available in the available evidence. Recency is uncertain because zero after-recent evidence window evidence were available. Caveats: Phase-2 rationale references, but no or summary is provided in the reviewed sources. Counterparty context should not be treated as propagated evidence for Neo Space Group's own thesis. Coverage debug shows zero evidence after recent evidence window. |
| 343 | NewOrbit lowweak | Opp 1 Risk 1 | Thesis: Reviewed evidence rationale says NewOrbit raised a £13.8 million Series A and is building VLEO sovereign communications satellites, but no retained evidence are present here to support a stronger ranked opportunity. Why now: No retained post-recent evidence window evidence are available, so current timing cannot be established from these reviewed sources. Caveats: Only membership rationale supports the company in this screen. No citeable retained evidence after recent evidence window. |
| 344 | OHB SE lowweak | Opp 1 Risk 1 | Thesis: No within the recent evidence window direct positive evidence was available, so there is insufficient reviewed sources support to form a positive 1 year+ opportunity thesis. Why now: There is no retained article or evidence row after the 90-day recent evidence window for OHB SE; recency-based ranking is therefore not supported by the reviewed sources. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Phase-2 cohort membership rationale is not directional evidence and cannot substitute for retained article evidence. Because no article were retained after recent evidence window, no company-specific factual thesis can be cited from these reviewed sources. |
| 345 | Optimized Electrotech Pvt Ltd lowweak | Opp 1 Risk 1 | Thesis: The membership rationale suggests funding and expansion into space-based sensing with initial satellite platform orders, but the reviewed sources provide no retained within the recent evidence window article evidence or to support a positive thesis. Why now: No retained company evidence after the 90-day recent evidence window means there is no evidence-set-backed timing reason to rank this name higher now. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale cites article IDs, and, but no or retained evidence text are available here. Without retained article evidence, absence of bad news is not positive evidence. |
| 346 | Orbex mediumweak | Opp 1 Risk 5 | Thesis: Orbex has only minimal current opportunity evidence in these reviewed sources because the cited article context about its Prime microlauncher predates the 90-day recent evidence window and therefore should not be relied on as current support. Why now: The only surfaced article is dated February 17, 2026, outside the reviewed sources cutoff date of March 29, 2026, and the evidence recent evidence review says both rows were dropped; the article summary said Orbex released new photographs of its microlauncher Prime 'as the company looks to secure a future'. Because this is outside recent evidence window, recency support is absent. Evidence
Caveats: Primary surfaced evidence is outside recent evidence window and should not be treated as current proof. No in-recent evidence window direct positive or negative evidence is available. |
| 347 | OrbitOn lowweak | Opp 1 Risk 1 | Thesis: OrbitOn appears in an external SpaceFund satellite-servicing listing as 'Developing an on-orbit satellite servicing solution,' which is relevant product context, but the article is dated March 4, 2025 and was dropped by the 90-day recent evidence window, so it cannot support a current scored opportunity thesis in these reviewed sources Why now: Why now is weak because the only visible article has March 4, 2025 on a source date basis and the reviewed sources report no current evidence was retained after the March 29, 2026 cutoff Evidence
Caveats: Only article detail shown is outside the 90-day recent evidence window and was dropped. Database/listing style evidence is weaker than company-specific event evidence. External supporting source context is relevance context, not stronger than direct retained evidence. |
| 348 | Palantir Technologies lowweak | Opp 1 Risk 2 | Thesis: This reviewed sources does not provide citable reviewed evidence to support an opportunity thesis for Palantir despite a membership rationale mentioning possible participation in a U.S. Space Force Golden Dome context. Why now: Why now is weak because the reviewed sources references article IDs, and in the membership rationale, but no or reviewed evidence are provided for ranking use. Caveats: High mention count is not conviction. Cohort relevance via Space Force context is not enough without direct event/fact evidence. Coverage debug shows zero evidence after recent evidence window despite large article universe. |
| 349 | Paras Defence and Space Technologies Ltd lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supported within the reviewed sources' 90-day evidence window. The only cited reviewed sources rationale is older context that the company incorporated a semiconductor subsidiary, but no within the recent evidence window direct positive evidence is available in these reviewed sources. Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Paras Defence and Space Technologies Ltd. Caveats: Phase-2 membership rationale references article, but the reviewed sources does not provide or quoted evidence for that item, so it cannot be used as a factual directional citation. No direct positive or negative evidence survived the 90-day recent evidence window. |
| 350 | Parsons Corporation lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources only provides older membership context that Parsons has 'space' among technology areas and appears in an SSA market report, but no within the recent evidence window direct positive evidence is available, so no positive thesis is supportable here. Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Parsons Corporation. Caveats: Phase-2 membership rationale references articles: and, but the reviewed sources provide no for citation. Article-level market-report inclusion is weaker than direct company-specific operating evidence. |
| 351 | PhysicsX lowweak | Opp 1 Risk 1 | Thesis: Phase-2 rationale says PhysicsX raised $300M, but the reviewed sources characterizes the source as a broad tech funding roundup and provides no retained direct positive evidence inside the 90-day window, so the opportunity case is not currently evidenced. Why now: There is no current catalyst evidence because articles after recent evidence window = 0 and evidence after recent evidence window = 0. Caveats: Funding-round context in rationale lacks -cited retained evidence here. Space relevance is explicitly weak in the reviewed sources rationale. |
| 352 | PierSight lowweak | Opp 1 Risk 1 | Thesis: Insufficient admissible reviewed sources evidence to support a positive thesis within the selected recent evidence window, despite membership rationale describing PierSight as building the Varuna 2.0 SAR and AIS maritime-monitoring satellite. Why now: Why now is unsupported because the reviewed sources show no surviving evidence after recent evidence filtering; there is no direct dated milestone or problem signal to anchor a 1 year+ thesis. Caveats: Only membership-level rationale is present; no citable evidence survived. No direct company-specific positive or negative events are available in the reviewed sources. Low scores reflect evidence scarcity. |
| 353 | Pixxel lowweak | Opp 1 Risk 1 | Thesis: The earlier Pixxel reviewed sources version suggests Earth-observation and fundraising relevance in membership rationale, but there are no retained within the recent evidence window evidence or article summaries to support a current opportunity thesis. Why now: Why now is weak because no articles or evidence were retained after the March 29, 2026 cutoff in these reviewed sources version. Caveats: Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Membership rationale references article IDs without, which cannot be cited as factual support here. |
| 354 | Portal Space Systems lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources' rationale mentions a $50 million Series A and maneuverable spacecraft technology, but no retained within the recent evidence window article evidence is present here to substantiate a positive thesis. Why now: There is no retained evidence inside the 90-day recent evidence window, so no current catalyst or business-state update is citable from these reviewed sources. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale references article IDs, and, but no or retained summaries are supplied. Low score reflects lack of citable evidence, not a negative business judgment. |
| 355 | Precursor SPC lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable from retained evidence. The phase-2 rationale says Precursor SPC uses Spire data for hypersonic tracking and an AI/ML ionospheric nowcasting system tied to article, but the reviewed sources provide no representative article details, quote, or and no retained evidence after recent evidence window. Why now: Why now is weak because the reviewed sources show no available post-recent evidence window evidence; evidence recent evidence review kept_rows is 0 and coverage data articles after recent evidence window is 0. Caveats: Phase-2 rationale references without or retained evidence detail, so it is not sufficient for factual grounding here. No direct positive or negative evidence arrays are populated. Low scores are an evidence-gap judgment, not a business conclusion. |
| 356 | Quantum Opus lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources references older membership support that Quantum Opus helped build a lunar-Earth laser communication terminal used on Artemis II via article, but there is no retained in-window direct positive evidence with to support a current opportunity thesis. Why now: There is no clear why-now catalyst because coverage after the 90-day recent evidence window is empty. Caveats: Membership support exists but no representative article is provided for. No retained evidence after recent evidence window. No direct business-state update, financing, contract, or customer traction evidence is available. |
| 357 | Quantum Systems GmbH lowweak | Opp 1 Risk 1 | Thesis: No direct positive evidence is available. The reviewed sources say Quantum Systems is mentioned only via founders investing in another startup and as a portfolio-company reference, which is not sufficient for a positive company thesis. Why now: There is no supported near-term or long-horizon catalyst in the reviewed sources because zero post-recent evidence window evidence were available. Caveats: Phase2 rationale references article IDs: and: as article context only, but no were provided in the reviewed sources. Coverage data shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Context-only mentions and portfolio references cannot substitute for direct positive or negative evidence. |
| 358 | Relativity Space lowweak | Opp 1 Risk 2 | Thesis: Relativity Space has a plausible long-horizon opportunity narrative as a rocket developer with financing context in membership rationale, but the reviewed sources contain no retained evidence within the recent evidence window to support a current opportunity call. Why now: Why now is weak because there are no retained post-cutoff article summaries or evidence in the reviewed sources. Caveats: No retained evidence after recent evidence window. The modest risk uplift reflects uncertainty from lack of current confirmation, not a direct adverse event. |
| 359 | Rocket Factory Augsburg lowweak | Opp 1 Risk 2 | Thesis: The membership rationale mentions focus on a first test launch later in the summer, which could be strategically important, but there is no retained evidence row to support a scored positive thesis. Why now: No retained article or event evidence remains after recent evidence filtering; the only hint is a membership rationale referencing first test-launch focus via article: without an included summary. Caveats: Cannot treat membership rationale alone as strong directional proof. No article summary or retained evidence row is included for article |
| 360 | Rogers Communications Inc. lowweak | Opp 1 Risk 1 | Thesis: Only a very weak opportunity read is possible: the reviewed sources rationale says Rogers was mentioned as a Starlink telco partner in a SpaceX IPO article, implying possible exposure to direct-to-device or satellite connectivity, but no in-recent evidence window company evidence or citable article summary were available for Rogers in these reviewed sources. Why now: There is no available 90-day evidence for Rogers in these reviewed sources; coverage data shows zero article ids after recent evidence window and zero evidence after recent evidence window, so there is no supported 'why now' catalyst in the provided evidence. Caveats: No direct positive or negative evidence were available after the 90-day recent evidence window for Rogers. Phase2 rationale references support references including: but no article or article summary for that item is included in these reviewed sources, so it cannot be cited as factual evidence. Opportunity score is kept near zero because the evidence standard require positive evidence, not mere absence of risk. |
Risk view
Showing rows 21-40 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 21 | Capella Space highstrong | Opp 8 Risk 4 | Thesis: Risk is present but not thesis-dominant: Capella is undertaking defense-oriented prototype work and broader strategic expansion beyond commercial SAR, which can carry execution complexity, but the reviewed sources contain no direct adverse evidence within the recent evidence window. Why now: The April 8, 2026 SDA award is recent within the recent evidence window and is directly relevant to a 1 year+ horizon because it funds spacecraft design and development for a government demonstration program. Later context articles in April-June 2026 continue to depict Capella as an operating SAR platform with defense exposure. Evidence
Caveats: The positive contract evidence is classified as a neutral supporting fact in the reviewed sources, so direction is inferred from the business substance rather than explicit positive polarity labeling. Several contextual articles mention a planned acquisition or subsidiary status, but time-sensitive ownership/public-status interpretations should be treated cautiously because not all such references are direct, dated transaction-closing evidence. For example, and |
| 22 | Cowboy Space mediummedium | Opp 7 Risk 4 | Thesis: Execution risk is meaningful because the business combines new rocket development with orbital data-center infrastructure, and one cited article says the first launch is expected before the end of 2028, implying a long path from capital raise to operational proof. Why now: Multiple dated articles on May 11, 2026 report Cowboy Space raised $275 million in Series B financing at a $2 billion valuation to build rockets with orbital data-center upper stages, and a TechCrunch article says the company is standing up its own rocket program with a first launch expected before end-2028 Evidence
Caveats: The reviewed sources contain no explicit negative event evidence; risk is inferred from execution complexity and long timeline, not from adverse events. Several supporting rows repeat the same May 11, 2026 financing story and are not independent confirmation. Some supporting article context is undated and should be treated cautiously for recency. |
| 23 | Eutelsat Communications SA mediummedium | Opp 7 Risk 4 | Thesis: Risk remains meaningful because the ranking payload contains no kept direct evidence or representative articles for those claims, so the thesis depends on membership-support statements without available article detail, economics, or recency granularity beyond inclusion in the recent evidence windowed reviewed sources. Why now: The reviewed sources' membership rationale cites current program/contract relevance through support articles 2026-04, and: but were not provided in the payload, limiting precise timing narration. Evidence
Caveats: The reviewed sources does not provide for the membership-support article IDs. Opportunity score is tempered by the absence of kept direct evidence in the ranking payload. |
| 24 | GalaxEye mediummedium | Opp 7 Risk 4 | Thesis: Risk remains meaningful because the reviewed sources does not provide direct evidence of post-launch operational performance, customer revenue conversion, or successful scaling beyond the first satellite. Funding references are inconsistent across articles, and planned next-round financing after commissioning indicates continued capital dependence. Why now: The key timing change is that earlier pre-launch coverage from April 23, 2026 was followed by launch coverage on May 3, 2026/May 4, 2026, and later June 16, 2026 context states the first satellite was launched in May 2026, confirming a business-state transition from concept/pre-launch to deployed asset status. The NSIL resale agreement was reported earlier on February 13, 2026, giving a potential go-to-market bridge once satellite data is available. Evidence
Caveats: Most reviewed sources rows are neutral facts or supporting article context rather than explicit positive evidence. Funding totals vary across articles (~$14.5M, $18.3M, ~$20M), so exact capitalization is uncertain |
| 25 | Globalstar lowweak | Opp 3 Risk 4 | Thesis: Risk is moderate because evidence coverage is absent inside the 90-day recent evidence window, making business-state, ownership, and catalyst timing uncertain for a 1 year+ ranking. Why now: There is effectively no why-now evidence in this row: the recent evidence review shows zero kept rows after the March 29, 2026 cutoff and no representative articles are provided. Caveats: The phase-2 rationale mentions Amazon acquisition-related articles, but those supporting articles are not included in the available evidence for this row. Scores remain low because absence of evidence is not positive evidence. |
| 26 | HyPrSpace lowweak | Opp 3 Risk 4 | Thesis: Risk is somewhat higher than opportunity because launch development is technically demanding and capital intensive, and the reviewed sources provide no available direct event evidence beyond the membership rationale to confirm de-risking milestones within the recent evidence window. Why now: The reviewed sources does not provide recent evidence window-supported article details for the cited raise and development milestones, so the timing case is under-evidenced. Caveats: No representative articles or direct evidence are available after recent evidence filtering. The opportunity view rests only on the membership rationale rather than article-level evidence available for citation. |
| 27 | Impulse Space mediummedium | Opp 8 Risk 4 | Thesis: Main risk is execution risk after a very large private financing round: the reviewed sources confirms capital raised, but does not provide within the recent evidence window direct evidence of completed commercial deployments or revenue realization. The article context says valuation was undisclosed, adding some uncertainty around terms and expectations. Why now: The catalyst is recent and dated: on June 2, 2026/June 3, 2026, Impulse Space disclosed a $500 million Series D and total capital raised above $1 billion, which is highly relevant for a 1 year+ scaling thesis. Evidence
Caveats: Some supportive items are supporting article context and should not be treated as independent confirmation if repeating the same financing announcement. Older commercial contract and government contract references in representative articles are outside the 90-day recent evidence window and therefore not primary recency support here. |
| 28 | Impulse Space lowweak | Opp 4 Risk 4 | Thesis: Risk is not based on direct adverse evidence; instead it reflects defense-program execution uncertainty and lack of currently available corroboration for program status, milestones, or revenue conversion, unavailable in reviewed sources). Why now: Why now is only medium because defense-space prototype work can matter over a 1 year+ horizon, but the reviewed sources' available evidence is empty after recent evidence window, preventing higher-conviction ranking. Caveats: No current evidence is provided for. No direct evidence remained after the recent evidence filter. Potential opportunity rests on membership rationale rather than available corroborated evidence. |
| 29 | Isar Aerospace mediummedium | Opp 5 Risk 4 | Thesis: Risk is also elevated because the same recent context ties the thesis to a near-term launch outcome and milestone execution; the opportunity appears highly contingent on launch success, making binary execution risk material over a 1 year+ horizon. Why now: Recent supporting article context within the recent evidence window supports timing: is dated June 9, 2026 and states Isar raised €270 million and had a June 15-21 Spectrum launch window from Andoya. Date basis is source date. Evidence
Caveats: Evidence is supporting article context only and appears under weak context, not direct dated events. Positive and risk interpretations come from the same article and are not independent confirmation. |
| 30 | ispace lowweak | Opp 3 Risk 4 | Thesis: Reviewed evidence rationale explicitly notes this is ispace's 'second attempt after 2023 failure,' which raises meaningful execution risk for a mission-driven thesis. With no direct positive or negative reviewed evidence, the prior failure context remains the clearest directional risk indicator in the reviewed sources. Why now: The membership support cites: and: The reviewed sources' wording around a second attempt makes mission outcome and execution durability relevant over a 1 year+ horizon, but timing confidence is reduced because no evidence survived into the available set. Caveats: Risk thesis is inferred from reviewed sources rationale mentioning a prior failure, not from available direct negative evidence. No direct evidence confirms current mission status, financing, or customer pipeline. Recency and sequencing of mission milestones cannot be validated from the empty evidence table. |
| 31 | Logos Space Services mediummedium | Opp 6 Risk 4 | Thesis: The same evidence implies substantial execution and engineering risk because the planned network is very large and would use higher-frequency K-, Q- and V-band spectrum that can improve capacity but also pose engineering challenges. Why now: A dated article within the 90-day recent evidence window, with based on April 13, 2026, states that Logos Space Services recently secured FCC approval for a constellation of up to 4,178 broadband satellites and described both target customers and technical architecture, making this a timely strategic-development signal for a 1 year+ horizon. Evidence
Caveats: Evidence is supporting article context, not a richer set of direct dated events/facts. Only one article after recent evidence window; same-article repeated rows are not independent confirmation. |
| 32 | Millennium Space Systems mediummedium | Opp 5 Risk 4 | Thesis: Risk remains moderate because the reviewed sources only provides supporting article context, not direct contract economics, scope allocation to Millennium, or follow-on execution milestones. Why now: The relevant evidence is within the recent evidence window: an April 8, 2026 article said the U.S. Space Force awarded 14 companies more than $1.8 billion in Andromeda contracts and included Boeing's Millennium Space Systems, which is potentially durable over a 1 year+ horizon if tasking converts into meaningful work Evidence
Caveats: Evidence is supporting article context, not a company-specific contract award document or structured positive event row. Reviewed evidence does not show Millennium's individual award size or share of the ceiling value. Same article repeated in weak-context rows is not independent confirmation. |
| 33 | NewOrbit Space mediummedium | Opp 4 Risk 4 | Thesis: Risk is also meaningful because the evidence is undated supporting article context, so recency is uncertain; for a business-state claim like financing and current program maturity, lack of date makes it harder to assess whether the capital raise is still a live catalyst or already absorbed. Why now: Why now is weaker than Aavuus because the article has no publication date. The reviewed sources explicitly says no is available and recency-sensitive claims should be treated cautiously., undated Evidence
Caveats: Evidence is supporting article context only, not direct structured positive event evidence. Publication date is unavailable; recency is uncertain. Single-article support only; no independent confirmation. |
| 34 | NordSpace lowweak | Opp 2 Risk 4 | Thesis: Main risk is evidence insufficiency and likely execution uncertainty around an early-stage space venture rather than confirmed adverse developments; the reviewed sources contain no available direct negative evidence within the recent evidence window and no current dated business-state confirmation, unavailable in reviewed sources). Why now: Why now is weak because coverage data shows zero articles after recent evidence window and zero evidence after the 90-day filter, so there is no current catalyst evidence to support a 1 year+ differentiated view from these reviewed sources. Caveats: No article is provided for the membership-support. No direct positive or negative evidence were available after recent evidence window. Private-company status reduces external validation in these reviewed sources. |
| 35 | NorthStar Earth & Space Inc. lowweak | Opp 2 Risk 4 | Thesis: This row carries elevated information risk because the reviewed sources show no recently retained evidence, no representative articles, and no direct positive or negative evidence, while the ticker/public status implications are time-sensitive and unsupported here. Why now: Why-now is weak because the evidence recent evidence review shows zero kept rows after the 90-day cutoff and the row contains no representative articles or direct evidence, so recency and business state are uncertain in these reviewed sources. Caveats: No evidence were available after the recent evidence window for this row. Any statement about public listing, SPAC timing, or operations would be insufficiently grounded from this row alone. Score is driven by evidence absence, not by documented adverse developments. |
| 36 | Northwood Space mediumweak | Opp 6 Risk 4 | Thesis: Risk is still moderate because the visible reviewed sources does not include the underlying article summary or, so the funding signal lacks fuller context such as use of proceeds, valuation, or milestone cadence. Why now: The rationale references article: and states Northwood Space raised $100 million in a notable spacetech funding deal; that size of financing is plausibly durable over a 1 year+ horizon, though recency cannot be fully validated from the absent article body. Caveats: No representative article or provided in the visible evidence body. No direct evidence after recent evidence window are exposed despite the positive rationale. Funding alone does not prove technical or commercial execution. |
| 37 | Obruta Space Solutions lowweak | Opp 4 Risk 4 | Thesis: Current risk is equal to opportunity because the reviewed sources only shows descriptive company-site context and no direct evidence of contracts, funding, launches, or technical milestones. Without validation, the thesis is still conceptual. Why now: The only dated visible evidence is a company-site page with a May 20, 2026 describing the technology and target markets, which is relevant for strategic positioning but not enough to prove commercial inflection within the next year. Evidence
Caveats: Evidence is company-site descriptive context only. No third-party validation, financing, contract, or deployment evidence is shown. |
| 38 | Observable Space lowweak | Opp 4 Risk 4 | Thesis: The reviewed sources provide no direct operating-niche detail, traction, or milestone evidence beyond the funding mention, so execution risk is relatively elevated despite the financing signal. Why now: Why now is the funding mention tied to article ID: but the reviewed sources provide no, operating specifics, or additional corroborating evidence. Caveats: Funding alone is positive evidence but does not prove business quality. Article ID: is referenced without. |
| 39 | Observable Space mediummedium | Opp 8 Risk 4 | Thesis: Risk remains meaningful because most evidence is supporting source context and neutral facts rather than explicit positive events, and the company still appears to be early-stage, contract-execution dependent, and private. Why now: The timing is favorable because on May 28, 2026 the company was reported to have both closed a $90 million Series A and announced a $94 million U.S. Space Force award, with additional follow-on reporting on June 9, 2026 indicating the contract landed just weeks after the raise, suggesting a recent step-change in funding and government traction for a 1 year+ horizon Evidence
Caveats: Positive direction is inferred from neutral facts plus article summaries; the reviewed sources does not provide explicit positive events. Same-article repeated rows are not independent confirmation. Supporting web-search evidence is context and should be treated below directly cited company evidence. |
| 40 | OMSPACE lowweak | Opp 4 Risk 4 | Thesis: Launch development risk is also high because the evidence only shows an early milestone and a future plan for orbital launch capability by 2027. The reviewed sources contain no retained proof of financing, customer backlog, or follow-on technical milestones, so execution risk is substantial. Why now: The reviewed sources' rationale references article: for a successful sounding-rocket launch and a 2027 orbital-launch target, but the underlying article summary/ is not included here, limiting recency and sequence assessment. Caveats: Evidence is limited to a broad membership rationale without article detail. A sounding-rocket success is meaningfully earlier-stage than an orbital launch business. Risk and opportunity are both elevated relative to peers because the technology path is ambitious but still lightly evidenced. |